Preview Mode Links will not work in preview mode
  1. All Episodes
  2. Metastatic Breast Cancer | Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer | Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

Nov 1, 2024

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics:

  • Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00)
  • Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18)
  • Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harboring ESR1 Mutations — Prof Bidard (35:52)

CME information and select publications